Background/aim To describe Australian physiotherapy and occupational therapy practice for patients who receive upper-limb Botulinum Toxin-A (BoNT-A). Method Anonymous online survey asking about practice experience. Convenience sample of 128 BoNT-A experienced occupational therapists and physiotherapists. Results The primary work setting was multidisciplinary inpatient or outpatient rehabilitation services where therapists had automatic referral to BoNT-A patients. Patients expected BoNT-A to improve functional movement, reduce hypertonicity, increase passive range, reduce pain, improve appearance and hand hygiene. Most patients were injected in multidisciplinary public hospital clinics and had median 2 pre-injection (range 0-30) and 8 post-injection (range 0-50) therapy sessions. Biceps, flexor digitorum profundus/superficialis and brachoradialis were most frequently injected. Injectors used therapist assessment information to select sites 68% of the time; only 44% of services had assessment protocols. Standardised therapy assessments examined motor performance, pain and function in that order of frequency. The greater the awareness and perceived relevance of an assessment the more often therapists used it. All therapists set goals, most collaboratively, and these mirrored patient expectations. The most common treatments were stretch, task-specific functional training, strength training and home programmes. Conclusion While trends in Australian assessment, goals and treatment practice were observed, greater consistency could be achieved if therapy practice guidelines existed. The gap is exacerbated by the absence of Australian BoNT-A organisation and process of care spasticity management guidelines. This creates an environment where practice variability is inevitable. Recommendations to improve local service quality are made.
INTRODUCTION
Upper limb spasticity is a common consequence of neurological events such as stroke.
Spasticity is "a motor disorder characterized by a velocity-dependent increase in tonic stretch reflexes (muscle tone) with exaggerated tendon jerks, resulting from hyper excitability of the stretch reflex" (Lance,1980,p.485) . It emerges over time (Lundström, Smits, Terént, & Borg,2010) , and can have devastating effects on quality of life through associated pain, limitations to passive and active movement, threats to skin integrity, difficulties in self-care and limb hygiene and in the long term, the potential for fixed contracture (Kong, Chua, & Lee,2010; Stevenson,2010) . Traditional occupational therapy and physiotherapy approaches to spasticity management have, more recently, been augmented by pharmacotherapy such as Botulinum toxin -A (BoNT-A) injections. BoNT-A has been demonstrated to be safe and effective in reducing focal spasticity in a range of neurological conditions (Delgado, Hirtz, Aisen et al.,2010; Muller, Cugy, Ducerf et al.,2012; Simpson, Gracies, Graham et al.,2008) . In Australia, the National Stroke Foundation (NSF) does not recommend BoNT-A for everyone with spasticity, rather, for those patients who have persistent moderate to severe spasticity that "interferes with activity or personal care" (NSF,2010)(Guide 7.3b). BoNT-A injection for post-stroke upper limb spasticity in Australia is subsidized through the government Pharmaceutical Benefits Scheme (PBS) "S100 Botulinum Toxin Program criteria for availability". To be eligible a patient with upper limb post-stroke spasticity requires an:-"MAS greater than or equal to 3 using modified Ashworth scale …as second line therapy when standard management has failed … or as an adjunct to physical therapy … [BoNT-A] treatment should be discontinued if the patient does not respond (decrease of MAS greater than 1 in at least one joint) after two treatments" (Department of Human Services Australian Government, 2012) .
Injection can only be done by a medical practitioner in Australia and this is usually a neurologist or rehabilitation physician.
BoNT-A for spasticity management can be used in isolation but researchers and peak rehabilitation bodies recommend multidisciplinary organisation of services and processes for care (Ozcakir & Sivrioglu,2007; Quinn, Paolucci, Sunnerhagen et al.,2009 ; Royal College of Physicians, British Society of Rehabilitation Medicine, Chartered Society of Physiotherapy, Association of Chartered Physiotherapists Interested in Neurology,2009; Sheean et al., 2010; Turner-Stokes & Ward 2009; Wissel, Gracies, Graham et al.,2008) . Multidisciplinary BoNT-A spasticity management processes of care should include the following elements: managing patient expectation, developing functional goals, using treatment plans and outcome measures, ensuring post-injection therapy review, implementing post-review treatment planning and providing self-management support (Allison & Knapp,2012) . To date little information about processes of care as evidenced by practice patterns is available (eg., Williams, Olver, De Graff, & Singer,2012 is the only study to date on Australian therapy BoNT-A related practice); and as yet practice guidelines for BoNT-A related therapy assessment and treatment have not been developed (Levy, Giuffrida, Richards et al.,2007; Sun, Hsu, Sun et al.,2010; Weber, Skidmore, Niyonkuru et al.,2010) . Evidence regarding post-stroke treatment effects in multidisciplinary spasticity management is also limited (Demetrios, Khan, Turner-Stokes, Brand & McSweeney,2013) . This study helps fill these evidence gaps by exploring BoNT-A related therapy practice in Australia, augmenting previous work (Williams et al., 2012) , by extending enquiry into factors relating to the organisation and process of care including injection and therapy settings, referral arrangements, muscles injected, assessments used and goal setting. Background information relating to these factors is now briefly reviewed.
Muscles injected: Currently, there are no Australian BoNT-A spasticity management guidelines to inform physician injection decisions. The Australasian Faculty of Rehabilitation Medicine (AFRM)(2009a) has only one position statement relating to use of BoNT-A (AFRM,2009b); this dates back to 1997 and it is not specific to spasticity management in adults. Although international BoNT-A spasticity management guidelines are available, the AFRM does not appear to have appraised or endorsed them. Australian injectors therefore set their own BoNT-A spasticity management standards and determine their own processes for site selection and post-injection follow-up. Injector preference, not factors such as patient goals or severity of spasticity, have been shown to underpin BoNT-A muscle site selection in Australia (Baguely, Nott, Turner-Stokes et al.,2011) .
Goals and Goal setting: Spasticity management should be goal directed and these goals should address function (NSF, 2010; Quinn et al.,2009; Royal College of Physicians et al,2009; Sheean et al.,2010; Turner-Stokes & Ward,2009; Wissel et al.,2010) . Goal-setting that involves patients, carers, therapists and physicians is also recommended (Allison & Knapp,2012; Royal College of Physicians et al.,2009) . Goal types can differ in frequency depending on spasticity recovery stage (Bakheit, Zakine, Maisonobe et al.,2010; Royal College of Physicians et al.,2009; Williams et al.,2012) .
In the early months of recovery the most common goal for BoNT-A treatment is active functional recovery, but in chronic spasticity management it is passive function. Pain relief is a common goal in both early and chronic spasticity conditions. Assessments: Assessment should help inform goal setting and evaluation of goal attainment.
Standardised functional assessments are however, rarely used in BoNT-A related therapy (Bakheit et al.,2010; Williams et al.,2012) . Instead, one Australian study found goal achievement was measured through patient or family self-report, standardised outcome measures that may not reflect activities of daily living, or non-standardised assessments (Williams et al.,2012) .
Treatment modalities: Therapy treatment for BoNT-A patients includes physical modalities
(such as sustained stretch using serial casting, orthoses, taping/strapping), strengthening, forced use motor training (constraint-induced movement therapy), repetitive task specific practice and/or mental practice, "movement based therapy", home exercise programs, electrical stimulation to agonist and injected muscles, and adaptation of activities or the environment to prevent and minimize adverse impact of spasticity on function (Ada, Dorsch, & Canning,2006; Demetrios et al.,2013; Katalinic, Harvey, Herbert et al.,2010; Page, Murray, & Hermann,2011; Treger, Aidinof, Lehrer, & Kalichman,2012; Williams et al.,2012) . Currently there are no modality-specific guidelines for treatment type, frequency or duration, nor is much known about current practice. Evidence of multidisciplinary rehabilitation effect is considered limited in scope and of low quality (Demetrios et al.,2013) . To date there has been debate about BoNT-A's contribution to attainment of functional goals (Caty, Detrembleur, Bleyenheuft et al.,2009; Cousins, Ward, Roffe et al.,2001; Delgado et al.,2010; Francis, Wade , Turner-Stokes et al.,2004; Galvin & Sakzewski,2011; Lai, Francisco, & Willis,2009; Patel,2011; Rosales, Kong, Goh et al.,2002) . At the same time there has been promising evidence that BoNT-A plus therapy may have sustained positive effects in spasticity reduction (Katalinic et al.,2010; Wolf, Milton, Reiss et al.,2012) and functional outcomes (Ada et al.,2006; Page et al.,2011; Treger et al.,2012) .
METHODS
This study aims to describe current Australian spasticity management practice by outlining the organisation and processes of care from a therapist perspective. To do this, an online anonymous selfreport survey was conducted with therapists who responded to a study invitation distributed through informal neuro-rehabilitation occupational therapy and physiotherapy networks in Australia. Recruitment took place after approval of researcher institutional research ethics committees. The study invitation specified that participants needed to be working in Australia, have upper limb neurological rehabilitation experience in the past five years, and experience working in services where patients had received
BoNT-A injections.
The author-designed survey asked demographic and clinical experience questions.
Organisation of BoNT-A care was explored through questions about: proportion of neuro-rehabilitation caseload that received BoNT-A, injection setting, referral process, patient access to therapy, therapy setting and service type. Processes of BoNT-A therapy care were examined by questions about: patient expectations; muscles injected; assessments used (rated as: not heard of it, never, rarely, sometimes, often, always); assessment relevance (rated as: don't know, essential must be included important, acceptable, marginal, not relevant shouldn't be included)(scale adapted from Clemson, Fitzgerald & Heard,1999; Skakun & King,1980) ; injector use of assessment information in site selection; whether or not the service had an assessment protocol; goal-setting; goals set (rated on: never, rarely, sometimes, often always); and treatment modalities used (rated on: never, rarely, sometimes, often, always). Even though BoNT-A cannot reduce contracture this was included in the goal questions because anecdotally it was reported to be in use.
Responses were submitted by participants into Survey Monkey™ and data was imported to SPSS Version 20 (IBM, 2011) . A value was allocated to Likert-type responses (higher values to higher ratings; not heard of it and don't know reported separately); item values were summed and then ranked to show trends. Comments were invited regarding other goals and whether or not all patients who receive BoNT-A receive therapy. Comments with the same or similar wording were grouped together so the range of the responses could be reported. In the case of patient expectations, the number of responses in each category was tallied to show trends. No question in the survey was compulsory.
Missing items are noted in the text or tables.
RESULTS
All participants (n=128) were university qualified; aged between 23 and 60 years (mean 33.5; median 32; SD 7.8). They were predominantly female occupational therapy clinicians working in capital cities in inpatient or outpatient rehabilitation services (Table 1) . Only 27.9% (n=33) worked some or all of the time in a BoNT-A clinic (n=85, 72% did not; n=10 missing). Most had worked with 10 or less BoNT-A injection patients in their career and 10% or less of their neurology caseload were injected patients.
Overall, participants (n=127) had significant total career (mean 11.5, median 10, SD8.1, range 1.5 to 40 years) and neurology (mean 8.9, median 7, SD7.8, range 7 months to 35 years) clinical experience. For most of the n=122 respondents, years of BoNT-A experience were less than half that of their neurology experience (mean 4.12, median 3, SD3.26, range 3 months to 15 years). In the past 12 months, 91.4% had seen neurological patients who had received upper limb BoNT-A injections and 58.6% had current BoNT-A patients.
Organisation of care
Overwhelmingly, BoNT-A injections were provided in public hospital BoNT-A spasticity management clinics (72%), with half of the patients receiving injections in multidisciplinary services (49.5%); a quarter were given in physician-only services (28.5%)( Table 2 ). Most therapists (58.5%) reported they could choose when they saw injected patients. Setting-specific automatic therapy referral known as "blanket referral" accounted for 23% (Table2). Participants were asked whether they thought all patients who had received BoNT-A injections received therapy and most said "no" (n=68 of 81 respondents; 84%).
Participants commented on issues they thought related to therapy access (Table 3) ; timely referral and team communication were important.
Process of care
Injections: Therapists reported most of their BoNT-A patients were 'first -time' BoNT-A recipients, (only 34% had repeat injections). Of 26 different upper limb muscles, participants reported that biceps, flexor digitorum profundus/ superficialis and brachoradialis were the most frequently injected (Table 4) . Those muscles at the top of the 'never injected' list were in descending order, rhomboids, extensor digitorum,and extensor carpi ulnaris. The muscles most often 'not known' about by therapists were levator scapulae and subscapularis.
Assessments: Most participants reported their clinic/workplace did not have assessment protocol they had to use (47.5%, n=61), 37% did (n=48) (n=19, 15% missing); but the overwhelming majority did assess their patients (all but 6 of 90 respondents; n=38 missing) before and after injection (n=60,67%).. Most therapists thought physicians used their assessment findings always or sometimes to select injection sites (n=61, 67.7%). Assessment awareness and frequency of use is presented in and then Goal Attainment Scaling. In general terms, greater use mirrored greater assessment awareness and perceived relevance.
Patient expectations: N=104 respondents described what they thought patients expected from their BoNT-A injection. In order from most to least frequent they were "active/functional movement/ dexterity" (n=43; 41.3%), improvement in hypertonicity/ tightness (n=19; 18.3%), increased passive range (n=18, 17.3%), reduction in pain (n=16; 15.4%), enhanced appearance (n=12, 11.5%), and improved hygiene (n=9, 8.6 %).
Goals: Participants (n=83; 45 missing) set goals either with (97.6%, n=81) or independent of (2.4%, n=2) patients and just over half of all patients had goals set before they were injected. There was a pattern in goal use: least used was increased upper limb dexterity, in increasing frequency was enhanced occupational therapy or physical therapy,enhanced cosmetic appearance of the upper limb, reduced contracture, increased upper limb active movement, reduced pain, and enhanced hygienic care was the most frequently used. N=47 participants identified other goals: the most frequent one, "enhanced function", was usually qualified with the descriptor "task specific". Some participants gave examples of these tasks (eg., dressing) or indicated that tasks were identified by patients. Other goals were: (a) to enhance position or posture, upper limb movement patterns, repetitive reciprocal exercise, tolerance of and ability to wear orthoses, balance and gait safety and/or sleep through decreased pain;
(b) maintain range of movement and/or joint integrity; (c) prevent contracture deterioration; and (d) decrease care-giver burden.
Treatment modalities: Nine treatment modalities were rated from never to always used (n=85; 43 missing). In order from low to high use they were: biofeedback, orthotic casts, electrical stimulation/ functional electrical stimulation, orthotic splints, movement training, home programs, strength training, task specific functional training and stretch. Sixteen therapists reported they used other treatments (a) constraint induced movement therapy, (b) task and strength movement training, (c) weight bearing stretches, (d) therapeutic positioning, (e) general fitness program and (f) compensation training for functional activities Treatment session frequency: Most patients were reported to receive pre-injection (mean 3.8,median 2, SD5.99, range 0 to 30 sessions; n=18, 24% had no pre-injection therapy) and postinjection sessions (mean 10.2,median 8, SD9.57, range 0 to 50; n=6, 5.6% had no post-injection therapy). To calculate the number of therapy sessions the following decision rules were used because participants answered the question in a variety of ways. In the case of pre-injection therapy sessions:
(a) n=67 participants gave a numerical estimate which was used; (b) n=5 gave a range and in this case the highest or the highest aggregate was used, eg. "1-6" was reported as 6 sessions while "1-6 weeks of 3-5 sessions/week" was reported as the function of 6 weeks by 5 sessions per week thus 30 sessions; (c) n=6 gave a weekly range eg., "3-5 per week", but because the number of weeks was not specified, a total could not be estimated so data was treated as missing;(d) n=31 gave no estimate but instead gave a description such as "variable/varies"=13, "daily"=5, "depends"=3, or some other word=10 such as "routine", "lots", "many", "several" and these were also treated as missing data; (e) n=19 did not answer. Thus 56 of 128 pre-injection therapy responses were treated as missing data. In the case of post-injection therapy sessions the same 'rules' applied: (a) n=44 gave a numerical estimate; (b) n=25 gave a range; (c) n=9 gave a weekly range but did not specify number of weeks; (d) n=26 gave a descriptor instead of an estimate eg., "variable/varies"=5, "depends"=4;; (e) n=24 did not answer. Thus 59 of 128 post-therapy responses were treated as missing data.
DISCUSSION
At present Australian therapists must practice in the absence of national BoNT-A spasticity management guidelines and without therapy-specific guidelines in particular. This is a challenge given our findings that BoNT-A therapy was both exceptional and relatively new for most therapists.
'Exceptional' in that most therapists had seen few BoNT-A patients in their careers and the proportion of their caseload receiving BoNT-A was small. 'New' in that most therapists had BoNT-A years of experience that were less than half that of their neurology practice. The practice variability we observed may be a consequence of this infrequent and relatively new exposure. But equally it may result from varying local approaches to care developed without AFRM guidance regarding 'model' processes and organizational arrangements for multidisciplinary care. One participant comment illustrates current gaps:-Most adult patients I have had experience with rarely see a therapist pre-injection. They also rarely receive post-injection therapy. If patients do have access to therapy services it is extremely uncommon that the therapist has the required skills to provide appropriate interventions such as casting, splinting and movement based interventions. The most significant issue is related to the model of service delivery for adults with a disability. Patient follow-up and monitoring over time is completely inadequate and patients are given their immediate post injection therapy and discharged. This is not appropriate for this patient population as their complex impairments need ongoing review and intervention Australian guidelines for BoNT-spasticity management and therapy specific guidelines are urgently required. Guidelines will provide a national benchmark for local practice improvement. Meanwhile therapists can improve their own process of care through professional development and consider implementing quality improvement activities to enhance local organization of care. The following recommendations provide a starting point for change.
This study demonstrated that most of the time, spasticity management was through multidisciplinary 'shared care' (NSF,2010; Wissel et al.,2008) . But a minority reported this NSF recommendation was not implemented, with physicians injecting without referring to therapy, or the There is promising evidence that BoNT-A plus therapy achieves positive results (Ada et al.,2006; Katalinic et al.,2010; Page et al.,2011; Treger et al.,2012; Wolf, Milton, Reiss et al.,2012) , but participants reported that injected patients do not always receive therapy. Local strategies to encourage and streamline therapy referral should be developed. Service organization could be improved by providing sufficient therapy resources to meet demand of BoNT-A injected patients. If therapy cannot be provided, services need to consider whether funds spent on BoNT-A alone are a wise spasticity management investment.
Services also need to consider whether the timing and amount of therapy they provide is appropriate and adequate. The NSF Guide 6.1.1a (NSF, 2010) recommends as much practice as possible within the first six months of stroke, unfortunately our study did not examine when therapy occurred in relation to the stroke. NSF Guide 6.1.1b (NSF, 2010) recommends at least one hour therapy per day at least five days a week for patients in 'active rehabilitation'; unfortunately our study did not examine service arrangements for therapy sessions. But our study did obtain an estimate of the number of therapy sessions patients typically received which was pre-injection mean 3.8 (median 2) post-injection mean 10.2 (median 8) and a quarter of participants reported no pre or post therapy.
Services should ensure that the number of pre-and post-injection therapy sessions, their timing in relation to the stroke event and their duration is monitored to help build an evidence base for future investigation.
Processes of care could be improved at a local level through development of service protocols for referral, assessment, site selection, goal setting, treatment and follow-up. Timing and type of referral varied in this study; greater consistency could minimize barriers to patient access to therapy when it is available. Injector use of assessment findings also varied -some chose sites unrelated to assessment findings and goals. Service protocols that encourage a link between assessment findings, collaboratively developed functional goals (Royal College of Physicians et al.,2009; NSF Guide 1.4.2b ; Wissel et al.,2008; ) and injection site selection would help facilitate a patient centered approach to spasticity management.
Processes of care could also be improved through professional development. Most services did not have assessment protocols and some participants did not use standardized assessments. While all participants set goals and most were functional, not all used functional assessments. The most frequently used assessments encompassed motor performance followed by pain and function. Greater use of standardized assessments, and functional assessments in particular would improve evidencebased decision-making and goal setting. Professional development may be required to enhance therapist knowledge of and skill in standardized functional assessment selection, administration and interpretation. This could be supported by service adoption of assessment protocols. One assessment illustrates the urgent need for professional development in assessment knowledge and skill. When compared with Williams et al. (2012) our sample had better uptake of the MAS, as only 45.7% of their sample used it. But given the critical role of the MAS as a threshold measure for PBS subsidy it would be expected that 100% of therapists should have used it and this was not the case. Australian therapists have previously reported their BoNT-A training was ad-hoc, gained through "lecture, seminar or workshop [attendance] related to Botulinum toxin injections and spasticity management" (Williams et al., 2012, p.259) . This further reinforces the need for targeted professional development.
Processes of care could also be improved by services developing local treatment protocols and professional development to enhance therapist capacity in administering treatment modalities. The most common interventions in this study were recommended modalities: stretch (Demetrios et al.,2013) , strength training (Guide 6.2.2), movement training and task-specific functional training (Guide 6.3.5a and b; Guide 6.4b), but consistency in approach is lacking without therapy guidelines.
Local treatment protocols may fill that gap. Home programs were also common but as a modality they are opaque: services need to make explicit what is in them, frequency, duration and intensity particularly in relation to NSF Guides 6.1.1e and 6.3.5a that relate to practice. Services can also describe why some recommended treatments are not used. CMIT, for example is supported by the NSF Guide 6.3.5a, but barriers to use have been identified (Viana & Teasell, 2012) .
Limitations: This study was limited by the self-report, anonymous and convenience sampling design. The survey itself brought limitations because it was not standardized and subsequent analysis of results has revealed gaps and problems in data coding that weaken the study. While all therapists provided demographic and most provided clinical setting responses, there were many missing responses -especially at the point in the survey where participants were asked to use Likert-type scales to rate multiple items. Between a quarter and a third of participants did not respond to ratings even though all participants continued "clicking through" survey pages so they could submit. Response drop may have been due to responder fatigue, time pressures, or questions could have been difficult to answer if participants were not aware of organization of services at their workplace, or if they or their service did not know about or use the range of assessments, goals and treatments identified.
In conclusion, although BoNT-A therapy practice varies in Australia, trends were evident. On the whole, if patients are referred for therapy, most will have a multidisciplinary team providing coordinated care in a publicly funded inpatient or outpatient rehabilitation setting. Patients will have treatment goals set collaboratively, and these will reflect patient expectations and will focus on function.
Standardized assessments will normally be used and assessments will collect information about patient motor performance, pain and function. Most patients will have home programs, but we don't know what these entail. Patients will receive therapy treatments that are generally consistent with NSF recommendations; however interventions lack strong evidence of effect. On the whole patients will receive more therapy sessions after injection than before, but more research is needed regarding session timing, frequency and duration. Development of Australian spasticity management guidelines or endorsement of international guidelines by peak professional bodies will provide a useful national benchmark for practice. Therapy guidelines can then be developed in a context where standards for organisation and processes of spasticity care are clear. Biceps 20 1 3 *If the sum of values was the same for different items, the same rank was used. 
